Clinical Trial Update: Estetrol/Drospirenone to Reduce the Average Size of Endometriomas [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating estetrol/drospirenone to reduce the average size of ovarian endometriomas; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrioma
• Ovarian Endometrioma

Drugs mentioned

• Estetrol/Drospirenone (Estetrol with drospirenone)

Snippet

Sponsor: Andrew Zakhari | Conditions: Ovarian Endometrioma, Endometrioma | Phase 4 | Status: RECRUITING